Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Baptiste LouveauMatthieu Resche-RigonThierry LesimpleLaetitia Da MedaMarc PrachtBarouyr BaroudjianJulie DelyonMona Amini-AdleCaroline DutriauxCoralie Reger de MouraAurélie SadouxFanélie JouenneZineb GhriebPaul VilquinDidier BoutonAnnick TibiSamuel HuguetKeyvan RezaïMaxime BattistellaSamia MourahCéleste LebbePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Although the combination of palbociclib + fixed-dose vemurafenib did not allow an increased palbociclib dosage above 25 mg, a significant clinical benefit was achieved in pretreated patients with melanoma. An association between the transcriptomic data and clinical response was highlighted.